Trial Profile

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Olaparib (Primary) ; Prednisolone (Primary) ; Prednisone (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms PROpel Study
Sponsors AstraZeneca

20 Mar 2024 Planned End Date changed from 31 Mar 2026 to 28 Apr 2026.
11 Oct 2023 According to an AstraZeneca media release, clinical data from this will be presented at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023.
01 Jun 2023 Results presented in an AstraZeneca Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com